Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A

British Journal of Pharmacology

Volumn 172, Issue 2, 2015, Pages 515-531

  Simonson, B ^a   Morani, A S ^a   Ewald, A W M ^a   Walker, L ^a   Kumar, N ^a   Simpson, D ^b   Miller, J H ^a   Prisinzano, T E ^b   Kivell, B M ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

addiction; cocaine self administration; dopamine transporter; drug seeking; nociception; Salvia divinorum; salvinorin A; opioid receptor

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; DOPAMINE TRANSPORTER; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; LONG ACTING DRUG; MESYL SAL B; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PERTUSSIS TOXIN; SALVINORIN A; UNCLASSIFIED DRUG; COCAINE; DITERPENE; MESYL SALVINORIN B; MESYLIC ACID DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOCAINE ACTIVITY; ARTICLE; BINDING AFFINITY; CELL SURFACE; CELL TRANSPORT; COCAINE DEPENDENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG ISOLATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SEEKING BEHAVIOR; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MAXIMUM REACTION VELOCITY; NONHUMAN; NUCLEUS ACCUMBENS; POTENTIOMETRY; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; AGONISTS; ANIMAL; BRAIN; CHLOROCEBUS AETHIOPS; COCAINE-RELATED DISORDERS; COS 1 CELL LINE; DRUG EFFECTS; DRUG SELF ADMINISTRATION; HEK293 CELL LINE; METABOLISM; MOTOR ACTIVITY; MOUSE; PAIN; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COCAINE; COCAINE-RELATED DISORDERS; COS CELLS; DITERPENES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG-SEEKING BEHAVIOR; HEK293 CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MESYLATES; MICE; MOTOR ACTIVITY; PAIN; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SELF ADMINISTRATION;

EID: 84920140188     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12692     Document Type: Article

References (92)

1. Al-Hasani R, Bruchas MR, (2011). Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115: 1363-1381.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Beguin C, Richards MR, Li JG, Wang Y, Xu W, Liu-Chen LY, et al. (2006). Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett 16: 4679-4685.
4. Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, Kiss A, et al. (2005). Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 280: 27662-27669.
5. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, Han Y, et al. (2007). D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 71: 1222-1232.
6. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, et al. (2008). Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 63: 286-292.
7. Braida D, Capurro V, Zani A, Rubino T, Vigano D, Parolaro D, et al. (2009). Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 157: 844-853.
8. Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, et al. (2007). Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 27: 11614-11623.
9. Bruchas MR, Xu M, Chavkin C, (2008). Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport 19: 1417-1422.
10. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, et al. (2011). Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71: 498-511.
11. Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ, (2007). Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther 320: 300-306.
12. Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ, (2009). Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328: 588-597.
13. Carlezon WA Jr, Beguin C, Dinieri JA, Baumann MH, Richards MR, Todtenkopf MS, et al. (2006). Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447.
14. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA JR, (2008). Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 33: 2676-2687.
15. Chavkin C, (2011). The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology 36: 369-370.
16. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, et al. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203.
17. Chefer V, Thompson AC, Shippenberg TS, (1999). Modulation of cocaine-induced sensitization by kappa-opioid receptor agonists. Role of the nucleus accumbens and medial prefrontal cortex. Ann N Y Acad Sci 877: 803-806.
18. Chefer VI, Moron JA, Hope B, Rea W, Shippenberg TS, (2000). Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine. Neuroscience 101: 619-627.
19. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR, (2015). Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol 172: 317-323.
20. Danielson K, Putt F, Truman P, Kivell BM, (2014). The effects of nicotine and tobacco particulate matter on dopamine uptake in the rat brain. Synapse 68: 45-60.
21. Dworkin S, Stairs D, (2002). Self-administration of drugs of abuse. In:, Waterhouse BD, (ed.). Methods in Drug Abuse Research: Cellular and Circuit Level Analyses. CRC Press: Boca Raton, pp. 17-49.
22. Ebner SR, Roitman MF, Potter DN, Rachlin AB, Chartoff EH, (2010). Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 210: 241-252.
23. Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, Gnegy M, (2009). Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. J Neurosci 29: 3328-3336.
24. Gehrke BJ, Chefer VI, Shippenberg TS, (2008). Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl) 197: 509-517.
25. Gray AM, Rawls SM, Shippenberg TS, McGinty JF, (1999). The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73: 1066-1074.
26. Graziane NM, Polter AM, Briand LA, Pierce RC, Kauer JA, (2013). Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity. Neuron 77: 942-954.
27. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, et al. (2007). An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 71: 549-557.
28. Harden MT, Smith SE, Niehoff JA, McCurdy CR, Taylor GT, (2012). Antidepressive effects of the kappa-opioid receptor agonist salvinorin A in a rat model of anhedonia. Behav Pharmacol 23: 710-715.
29. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, et al. (2005). Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem 48: 4765-4771.
30. John TF, French LG, Erlichman JS, (2006). The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 545: 129-133.
31. Johnson MW, Maclean KA, Reissig CJ, Prisinzano TE, Griffiths RR, (2011). Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115: 150-155.
32. Jordan BA, Devi LA, (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700.
33. Kane BE, McCurdy CR, Ferguson DM, (2008). Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem 51: 1824-1830.
34. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
35. Kivell B, Day D, Bosch P, Schenk S, Miller J, (2010). MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation. Neuroscience 168: 82-95.
36. Kivell BM, Ewald AW, Prisinzano TE, (2014). Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol 69: 481-511.
37. Kmiotek EK, Baimel C, Gill KJ, (2012). Methods for intravenous self administration in a mouse model. J Vis Exp. doi: 10.3791/3739.
38. Koob GF, Le Moal M, (2008). Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
39. Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE, et al. (2014). Addiction as a stress surfeit disorder. Neuropharmacology 76 (Pt B): 370-382.
40. Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, Messinger D, et al. (2009). Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci U S A 106: 19168-19173.
41. Lovell KM, Prevatt-Smith KM, Lozama A, Prisinzano TE, (2011). Synthesis of neoclerodane diterpenes and their pharmacological effects. Top Curr Chem 299: 141-185.
42. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ, (2006). Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83: 109-113.
43. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
44. McLaughlin JP, Marton-Popovici M, Chavkin C, (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683.
45. McLennan GP, Kiss A, Miyatake M, Belcheva MM, Chambers KT, Pozek JJ, et al. (2008). Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem 107: 1753-1765.
46. Meiergerd SM, Schenk JO, (1994). Striatal transporter for dopamine: catechol structure-activity studies and susceptibility to chemical modification. J Neurochem 62: 998-1008.
47. Melief EJ, Miyatake M, Bruchas MR, Chavkin C, (2010). Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 107: 11608-11613.
48. Mello NK, Negus SS, (1998). Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286: 812-824.
49. Morani AS, Kivell B, Prisinzano TE, Schenk S, (2009). Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 94: 244-249.
50. Morani AS, Schenk S, Prisinzano TE, Kivell BM, (2012). A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behav Pharmacol 23: 162-170.
51. Morani AS, Ewald A, Prevatt-Smith KM, Prisinzano TE, Kivell BM, (2013). The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats. Eur J Pharmacol 720: 69-76.
52. Moron JA, Zakharova I, Ferrer JV, Merrill GA, Hope B, Lafer EM, et al. (2003). Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 23: 8480-8488.
53. Mowry M, Mosher M, Briner W, (2003). Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs 35: 379-382.
54. Muschamp JW, Van't Veer A, Carlezon WA JR, (2011). Tracking down the molecular substrates of stress: new roles for p38alpha MAPK and kappa-opioid receptors. Neuron 71: 383-385.
55. Negus SS, Mello NK, Portoghese PS, Lin CE, (1997). Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282: 44-55.
56. Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, Stout A, et al. (2010). Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci 30: 14153-14164.
57. Potter DN, Damez-Werno D, Carlezon WA Jr, Cohen BM, Chartoff EH, (2011). Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 70: 744-753.
58. Povlock SL, Schenk JO, (1997). A multisubstrate kinetic mechanism of dopamine transport in the nucleus accumbens and its inhibition by cocaine. J Neurochem 69: 1093-1105.
59. Prevatt-Smith KM, Prisinzano TE, (2010). New therapeutic potential for psychoactive natural products. Nat Prod Rep 27: 23-31.
60. Prevatt-Smith KM, Lovell KM, Simpson DS, Day VW, Douglas JT, Bosch P, et al. (2011). Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. Medchemcomm 2: 1217-1222.
61. Prisinzano TE, (2005). Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78: 527-531.
62. Prisinzano TE, Rothman RB, (2008). Salvinorin A analogs as probes in opioid pharmacology. Chem Rev 108: 1732-1743.
63. Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, et al. (2012). Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biol Psychiatry 72: 871-879.
64. Richards TL, Zahniser NR, (2009). Rapid substrate-induced down-regulation in function and surface localization of dopamine transporters: rat dorsal striatum versus nucleus accumbens. J Neurochem 108: 1575-1584.
65. Roitman MF, Patterson TA, Sakai RR, Bernstein IL, Figlewicz DP, (1999). Sodium depletion and aldosterone decrease dopamine transporter activity in nucleus accumbens but not striatum. Am J Physiol 276: R1339-R1345.
66. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, et al. (2002). Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99: 11934-11939.
67. Schenk S, Partridge B, (1999). Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl) 147: 285-290.
68. Schenk S, Partridge B, (2000). Sensitization to cocaine's reinforcing effects produced by various cocaine pretreatment regimens in rats. Pharmacol Biochem Behav 66: 765-770.
69. Schenk S, Partridge B, Shippenberg TS, (1999). U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144: 339-346.
70. Schenk S, Partridge B, Shippenberg TS, (2000). Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl) 151: 85-90.
71. Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM, (2013). Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at kappa-opioid receptors in striatal neurons. J Biol Chem 288: 22387-22398.
72. Schmidt HD, Anderson SM, Famous KR, Kumaresan V, Pierce RC, (2005). Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking. Eur J Pharmacol 526: 65-76.
73. Schwartz JW, Blakely RD, Defelice LJ, (2003). Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate. J Biol Chem 278: 9768-9777.
74. Shippenberg TS, Zapata A, Chefer VI, (2007). Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116: 306-321.
75. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, et al. (1998). Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17: 886-897.
76. Spanagel R, Herz A, Shippenberg TS, (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55: 1734-1740.
77. Spangler R, Zhou Y, Maggos CE, Schlussman SD, Ho A, Kreek MJ, (1997). Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute 'binge' cocaine. Brain Res Mol Brain Res 44: 139-142.
78. Sperling RE, Gomes SM, Sypek EI, Carey AN, McLaughlin JP, (2010). Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration. Psychopharmacology (Berl) 210: 199-209.
79. Su D, Riley J, Armstead WM, Liu R, (2012). Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via extracellular signal-regulated kinase/mitogen-activated protein kinase in piglets. Anesth Analg 114: 200-204.
80. Svingos AL, Chavkin C, Colago EE, Pickel VM, (2001). Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42: 185-192.
81. Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, et al. (2009). Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 72: 471-477.
82. Thompson AC, Zapata A, Justice JB Jr, Vaughan RA, Sharpe LG, Shippenberg TS, (2000). Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20: 9333-9340.
83. Thompson GL, Kelly E, Christopoulos A, Canals M, (2015). Novel GPCR paradigms at the mu-opioid receptor. Br J Pharmacol 172: 287-296.
84. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R, (2002). Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135: 564-578.
85. Van't Veer A, Carlezon WA Jr, (2013). Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl) 229: 435-452.
86. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, et al. (2005). Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312: 220-230.
87. Wee S, Koob GF, (2010). The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 210: 121-135.
88. Wee S, Orio L, Ghirmai S, Cashman JR, Koob G, (2009). Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl) 205: 565-575.
89. Wu Q, Reith ME, Kuhar MJ, Carroll FI, Garris PA, (2001). Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci 21: 6338-6347.
90. Yoshizawa K, Narita M, Saeki M, Narita M, Isotani K, Horiuchi H, et al. (2011). Activation of extracellular signal-regulated kinase is critical for the discriminative stimulus effects induced by U-50,488H. Synapse 65: 1052-1061.
91. Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, Kuraguntla D, et al. (2007). Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282: 35842-35854.
92. Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, et al. (2013). Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288: 36703-36716.